Report on a trial of SCG 2% nasal solution (metered dose) in hayfever

An analysis has been performed on the results from 18 patients treated with SCG and 14 patients treated with placebo in a double-blind placebo-controlled group comparative trial of SCG 2% nasal solution (metered dose) in hayfever. The two treatment groups were found to be similar with respect to relevant characteristics and pre-trial symptomatology. Analysis of clinician's symptom scorings demonstrated statistically significant differences in favour of SCG for the symptoms Sneezing, Running and Itching. No significant differences between the treatments were found in the statistical analysis of patient diary card total scores. Five assessments of overall response made at the end of treatment gave results highly significantly in favour of SCG.